Leucocyte nadir as a marker for chemotherapy efficacy in node-positive breast cancer treated with adjuvant CMF

British Journal of Cancer

Volumn 80, Issue 11, 1999, Pages 1763-1766

  Poikonen, P ^a   Saarto, T ^a   Lundin, J ^a   Joensuu, H ^a   Blomqvist, C ^a  

^a HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

Author keywords

Adjuvant chemotherapy; Breast neoplasms; CMF; Leucopenia

Indexed keywords

CYCLOPHOSPHAMIDE; FLUOROURACIL; METHOTREXATE; PROGESTERONE RECEPTOR; TAMOXIFEN;

ADULT; AGE; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; DRUG EFFICACY; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LEUKOCYTE COUNT; LEUKOPENIA; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROGNOSIS; STATISTICAL ANALYSIS; SURGICAL TECHNIQUE; TREATMENT OUTCOME; TUMOR VOLUME;

ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; CYCLOPHOSPHAMIDE; DISEASE-FREE SURVIVAL; DRUG MONITORING; FEMALE; FLUOROURACIL; FOLLOW-UP STUDIES; HUMANS; LEUKOCYTE COUNT; LEUKOPENIA; LIFE TABLES; LYMPHATIC METASTASIS; METHOTREXATE; MIDDLE AGED; NEOPLASM STAGING; PREDICTIVE VALUE OF TESTS; RECEPTORS, PROGESTERONE; SURVIVAL RATE; TIME FACTORS;

EID: 0032774739     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjc.6690594     Document Type: Article

References (22)

1. Ahmann DL, O'Fallon JR, Scanlon PW, Payne WS, Bisel HF, Edmonson JH, Frytak S, Hahn RG, Ingle JN, Rubin J and Creagan ET (1982) A preliminary assessment of factors associated with recurrent disease in a surgical adjuvant clinical trial for patients with breast cancer with special emphasis on the aggressiveness of therapy. Am J Clin Oncol 5: 371-381
2. Ang PT, Buzdar AU, Smith TL, Kau S and Hortobagyi GN (1989) Analysis of dose intensity in doxorubicin-containing adjuvant chemotherapy in stage II and III breast carcinoma. J Clin Oncol 7: 1677-1684
3. Bonadonna G and Valagussa P (1981) Dose-response effect of adjuvant chemotherapy in breast cancer. N Engl J Med 304: 10-15
4. Colleoni M, Price K, Castiglione-Gertch A, Goldhirch A and Coates A (1998) Dose response effect of adjuvant cyclophosphamide, methotrexale, 5-fluorouracil (CMF) in node-positive breast cancer. Eur J Cancer 34: 1693-1700
5. Cox D (1972) Regression models and life tables. J R Statist Soc Sci B34: 187-220
6. Early Breast Cancer Trialists' Collaborative Group (1992) Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy: 133 randomised trials involving 31 000 recurrences and 24 000 deaths among 75 000 women. Lancet 339: 1-15
7. Fisher B, Anderson S, Wickerham DL, DeCillis A, Dimitrov N, Mamounas E, Wolmark N, Pugh R, Aikins JN, Meyers FJ, Abramson N, Wolter J, Bornstein RS, Levy L, Romond EH, Caggiano V, Grimaldi M, Jochimsen P and Deckers P (1997) Increased intensification and total dose ot cyclophosphamide in a doxorubicin-cyclophosphamide regimen for the treatment of primary breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-22. J Clin Oncol 15: 1858-1869
8. Fumoleau P, Devaux Y, Vo VM, Kerbrat P, Fargeot P, Schraub S, Mihura J, Namer M and Mercier M (1993) Premenopausal patients with node-positive resectable breast cancer. Preliminary results of a randomised trial comparing 3 adjuvant regimens: FEC 50 × 6 cycles vs FEC 50 × 3 cycles vs FEC 75 × 3 cycles. The French Adjuvant Study Group. Drugs 2: 38-45
9. Glucksberg H, Rivkin SE, Rasmussen S, Tranum B, Gad El, Mawla N, Costanzi J, Hoogstraten B, Athens J, Maloney T, McCracken J and Vaughn C (1982) Combination chemotherapy (CMFVP) versus L-phenylalanine mustard (LPAM) for operable breast cancer with positive axillary nodes: a Southwest Oncology Group Study. Cancer 50: 423-434
10. Howell A, Rubens R and Bush H (1984) A controlled trial of adjuvant chemotherapy with melphalan versus cyclophosphamide, methotrexate and fluorouracil for breast cancer. Resent Results Cancer Res 96: 74-89
11. Kaplan E and Meier P (1958) Non-parametric estimation from incomplete observations. J Am Statist Assoc 53: 457-481
12. Longo DL, Duffey PL, DeVita VJ, Wesley MN, Hubbard SM and Young RC (1991) The calculation of actual or received dose intensity: a comparison of published methods. J Clin Oncol 9: 2042-2051
13. Mouridsen HT, Rose C, Brincker H, Thorpe SM, Rank F, Fischerman K and Andersen KW (1984) Adjuvant systemic therapy in high-risk breast cancer: the Danish Breast Cancer Cooperative Group's trials of cyclophosphamide or CMF in premenopausal and tamoxifen in postmenopausal patients. Recent Results Cancer Res 96: 117-128
14. Peto R, Pike M and Armitage P (1977) Dosing and analysis of randomized clinical trials requiring prolonged observation of each patient. II. Analysis and examples. Br J Cancer 35: 1-39
15. Pronzato P, Campora E, Amoroso D, Bertelli G, Botto F, Conte PF, Sertoli MR and Rosso R (1989) Impact of administration-related factors on outcome of adjuvant chemotherapy for primary breast cancer. Am J Clin Oncol 12: 481-485
16. Redmond C, Fisher B and Wieand HS (1983) The methodologic dilemma in retrospectively correlating the amount of chemotherapy received in adjuvant therapy protocols with disease-free survival. Cancer Treatment Rep 67: 519-526
17. Rodriguez KR, Hortobagyi GN, Buzdar AU and Blumenschein GR (1981) Combination chemotherapy for breast cancer metastatic to bone marrow. Cancer 48: 227-232
18. Saarto T, Blomqvist C, Rissanen P, Auvinen A and Elomaa I (1997) Haematological toxicily: a marker of adjuvant chemotherapy efficacy in stage II and III breast cancer. Br J Cancer 75: 301-305
19. Senn H, Jungi W and Amgewerd R (1984) Adjuvant chemoimmunotherapy with LMF + BCG in node negative and node positive breast cancer. 8 year results. Recent Results Cancer Res 96: 90-101
20. Tormey D, Gelman R and Falkson G (1983) Prospective evaluation of rotating chemotherapy in advanced breast cancer. An Eastern Cooperative Oncology Group Trial. Am J Clin Oncol 6: 1-18
21. Velez-Garcia E, Carpenter J and Moore M (1987) Postsurgical adjuvant chemotherapy with or without radiotherapy in women with breast cancer and positive axillary nodes: Progress report of Southeastern Cancer Study Group (SEG) trial. Adjuvant Ther Cancer V: 347-355
22. Wood WC, Budman DR, Korzun AH, Cooper MR, Younger J, Hart RD, Moore A, Ellerton JA, Norton L, Ferree CR, Colangelo Ballow A, Frei III E and Henderson C (1994) Dose and dose intensity of adjuvant chemotherapy for stage II, node-positive breast carcinoma N Engl J Med 330: 1253-1259